
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon is poised for strong growth with positive bookings, a strong focus on larger and more stable clients, and a solid financial position with planned debt payments. Management's confidence in continued earnings improvement and potential guidance raise bodes well for the company's future success. The company's global reach and diverse range of services make it a strong player in the contract research organization market, and its partnerships with life sciences firms provide a strong foundation for continued growth and success.
Bears say
Icon is facing intense competition in the CRO market, and its cancellation levels and direct-fee revenue remain unchanged despite strong commercial performance and higher than expected passthrough revenue. Additionally, the company's 2Q26 results reflect a decline in direct-fee revenue and an increase in passthrough revenue, which could impact future reported revenue and margins. Furthermore, while the company sets ambitious sustainability targets, its materiality assessment identifies access to clinical trials, diversity and inclusion, and climate change as key priorities, indicating potential challenges in these areas.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares